Banner_homepage.jpg

The Genetic Disease Company

GeneToBe's Mission

Preclinical and Clinical Stage Assets
Proof of concept in preclinical in vivo models
 
Technology
Next generation CRISPR/Cas9 platform (miCas9)
Create translational rare genetic disease models for demonstrating preclinical efficacy


Management
Team with over 150 years’ experience in drug discovery, development, registration, and commercialization that has produced multiple registered pharmaceutical products and candidates